This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bryson Y.J., Pang S., Wei L.S., et al., 1995, Clearance of HIV infection in a perinatally infected infant. N Engl J Med 332: 833–838.
Chertova E., Bess J.W. Jr., Crise B.J., et al., 2002, Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type-1 and simian immunodeficiency virus. J Virol 76: 5315–5325.
Clerici M., Levin J.M., Kessler H.A., et al., 1994, HIV-specific T-helper activity in sero-negative health care workers exposed to contaminated blood. JAMA 271: 42–46.
Davis N.L., West A., Reap E., et al., 2002, Alpha virus replicon particles as candidate HIV vaccines. IUBMB Life 53: 209–211.
Desrosiers R.C., 2004, Prospects for an AIDS vaccine. Nature Med 10: 221–223.
Excler J.L., 2005, AIDS Vaccine development: perspectives, challenges and hopes. Indian J Med Res 121(4): 568–581.
Fanales-Belasio E., Cafaro A., Cara A., et al., 2002, HIV-1 Tat-based vaccines: from basic science to clinical trials. DNA Cell Biol 21: 599–610.
Fouts T.R., De Vico A.L., Onyabe D.Y., et al., 2003, Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol Med Microbiol 37: 129–134.
Gahery-Segard H., Pialoux G., Figueiredo S., et al., 2003, Long-term specific immune responses induced in humans by a human immunodeficiency virus type-1 lipopeptide vaccine: Characterization of CD8+ T-cell epitopes recognized. J Virol 77: 11220–11231.
Gaillard P., Fowler M.G., Dabis F., et al., 2004, Use of anti-retroviral drugs to prevent HIV-1 transmission through breast-feeding: from animal studies to randomized clinical trials. J AIDS 35: 178–187.
Girard M.F., Mastro T.D., and Koff W., 2004, Human Immunodeficiency Virus. In: Vaccines (S.A. Plotkin and W.A. Orenstein eds.). Philadelphia: Saunders, pp 1219–1258.
Harries A., Maher D., and Graham S., 2004, TB/HIV – a clinical manual 2nd edn. Geneva: WHO. pp 137–154.
Hirsh V.M., Goldstein S., Hynes N.A., et al., 1994, Prolonged clinical latency and survival of macaques given whole inactivated simian immunodeficiency virus vaccine. J Infect Dis 170: 51–59.
IAVI Report, 2006, Ongoing trials of preventive AIDS vaccines. VAX 4(1): 1–2. www.iavireport.org.
Im E.J. and Hanke T., 2004, MVA as a vector for vaccines for HIV-1. Expert Rev Vaccines 3 Suppl 1: S89–S97.
Kent S.J., Clancy R.L., and Ada G.L., 1997, Prospects for a preventive HIV vaccine. In: Managing HIV (G.J. Stewart ed.). North Sydney: Australasian Medical Publishing, pp 179–182.
Kozlowski P.A. and Neutra M.R., 2003, The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 3: 217–228.
Liu R., Paxton W.A., Choe S., et al., 1996, Homozygous defect in HIV-1 co-receptor accounts for resistance in some multiple-exposed individuals to HIV-1 infection. Cell 86: 367–377.
Muthuswamy V., 2005, Ethical issues in HIV/AIDS research. Indian J Med Res 121(4): 601–610.
Philips R.E., Rowland-Jones S.L., Nixon D.F., et al., 1991, HIV genetic variation that can escape CTL recognition. Nature 354: 453–457.
Rowland-Jones S.L., Nixon D.F., Ariyoshi K., et al., 1993, HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 341: 860–861.
Rowland-Jones S.L., Sutton J., Ariyoshi K., et al., 1995, HIV-specific cytotoxic T-cell activity in HIV-exposed but uninfected Gambian women. Nature Med 1: 59–64.
Singh S.K. and Bisen P.S., 2006, Adjuvanticity of stealth liposomes on the immunogenicity of synthetic gp41 epitope of HIV-1. Vaccine 24: 4161–4166.
Thorne C. and Newell M.L., 2004, Prevention of mother-to-child transmission of HIV infection. Curr Opin Infect Dis 17: 247–252.
UNAIDS, 2000, Ethical considerations in HIV preventive vaccine research. UNAIDS Guidance Document. Geneva: UNAIDS.
Whitney J.B. and Ruprecht R.M., 2004, Live attenuated HIV vaccines – pitfalls and prospects. Curr Opin Infect Dis 17: 17–26.
Wig N., 2002, Anti-retroviral therapy – are we aware of adverse effects? JAPI 50: 1163–1171.
Zhu T., Mo H., Wang N., et al., 1993, Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261: 1179–1181.
Rights and permissions
Copyright information
© 2007 Springer
About this chapter
Cite this chapter
(2007). Preventive HIV Vaccine. In: HIV and AIDS: Basic Elements and Priorities. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5789-2_25
Download citation
DOI: https://doi.org/10.1007/978-1-4020-5789-2_25
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-5788-5
Online ISBN: 978-1-4020-5789-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)